| Completed | A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-do NCT02447432 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyop NCT02270944 | GlaxoSmithKline | Phase 2 |
| Completed | Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With NCT02838407 | GlaxoSmithKline | N/A |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When A NCT01746108 | GlaxoSmithKline | Phase 3 |
| Completed | Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media (AOM) in Children Aged 6 Months to L NCT01793857 | GlaxoSmithKline | — |
| Withdrawn | Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey NCT01031329 | GlaxoSmithKline | — |
| Withdrawn | Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children NCT01160055 | GlaxoSmithKline | — |
| Completed | Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synfl NCT01641133 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) NCT01616459 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children NCT01545375 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administer NCT01485406 | GlaxoSmithKline | Phase 1 |
| Completed | To Evaluate the Incidence of Acute Otitis Media in Children in Five East European Countries NCT01365390 | GlaxoSmithKline | — |
| Completed | Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A NCT01175083 | GlaxoSmithKline | Phase 3 |
| Completed | Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam NCT01153841 | GlaxoSmithKline | Phase 3 |
| Completed | Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & NCT01262872 | GlaxoSmithKline | Phase 2 |
| Completed | Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea NCT01248988 | GlaxoSmithKline | — |
| Completed | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treat NCT01235949 | GlaxoSmithKline | Phase 4 |
| Completed | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children NCT01153893 | GlaxoSmithKline | Phase 3 |
| Completed | Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infa NCT01204658 | GlaxoSmithKline | Phase 2 |
| Completed | Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose NCT01119625 | GlaxoSmithKline | Phase 3 |
| Terminated | Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines NCT01046097 | GlaxoSmithKline | — |
| Completed | Booster and Catch-up Vaccination With Vaccine GSK1024850A NCT01030822 | GlaxoSmithKline | Phase 3 |
| Completed | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children NCT01027845 | GlaxoSmithKline | Phase 3 |
| Completed | Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Va NCT00985751 | GlaxoSmithKline | Phase 2 |
| Completed | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children NCT00985465 | GlaxoSmithKline | Phase 3 |
| Completed | Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unp NCT00950833 | GlaxoSmithKline | Phase 3 |
| Completed | Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ NCT00907777 | GlaxoSmithKline | Phase 3 |
| Completed | Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine NCT00911144 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Saudi NCT01204385 | GlaxoSmithKline | — |
| Completed | Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults NCT00896064 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disea NCT00861380 | GlaxoSmithKline | Phase 3 |
| Completed | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age NCT00814710 | GlaxoSmithKline | Phase 3 |
| Completed | Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 102 NCT00839254 | GlaxoSmithKline | Phase 3 |
| Completed | Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and NCT00829010 | GlaxoSmithKline | Phase 3 |
| Completed | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age NCT00808444 | GlaxoSmithKline | Phase 3 |
| Completed | Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A NCT00792909 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Pneumococcal Vaccine Formulations in Elderly NCT00756067 | GlaxoSmithKline | Phase 1 |
| Completed | Evaluation of Pneumococcal Vaccine Formulations in Young Adults NCT00707798 | GlaxoSmithKline | Phase 1 |
| Completed | Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio NCT00678301 | GlaxoSmithKline | Phase 3 |
| Completed | Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and NCT00680914 | GlaxoSmithKline | Phase 3 |
| Completed | Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-I NCT00652951 | GlaxoSmithKline | Phase 3 |
| Completed | Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine NCT00624819 | GlaxoSmithKline | Phase 3 |
| Completed | A Study in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays NCT00637351 | GlaxoSmithKline | — |
| Completed | Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants NCT00609492 | GlaxoSmithKline | Phase 3 |
| Completed | Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines NCT00547248 | GlaxoSmithKline | Phase 3 |
| Completed | Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. Pneumoni NCT00523770 | GlaxoSmithKline | — |
| Completed | Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up NCT00513409 | GlaxoSmithKline | Phase 2 |
| Completed | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age NCT00489554 | GlaxoSmithKline | Phase 3 |
| Completed | Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK102 NCT00496015 | GlaxoSmithKline | Phase 3 |
| Completed | COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the NCT00466947 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine NCT00370227 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infan NCT00390910 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine NCT00370396 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine NCT00345358 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine NCT00344318 | GlaxoSmithKline | Phase 3 |
| Completed | Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines. NCT00333450 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine NCT00334334 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Popu NCT00327665 | GlaxoSmithKline | Phase 1 |
| Completed | Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedu NCT00307034 | GlaxoSmithKline | Phase 3 |
| Completed | A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiori NCT00307554 | GlaxoSmithKline | Phase 3 |
| Completed | Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine NCT00307541 | GlaxoSmithKline | Phase 3 |